Sure Petcare Announces Launch of New FELAQUA® CONNECT in United States

Smart Device Accurately Monitors your Cat’s Drinking Behavior

MADISON, N.J., (July 1, 2021) — Sure Petcare, the leading pet technology specialist, has announced today the launch of the latest product in its connected range, FELAQUA® CONNECT – a unique water delivery and drinking monitoring system for cats. FELAQUACONNECT, designed in collaboration with leading veterinary behaviorists, allows cat owners to keep track of their cats’ daily water intake via the SURE PETCARETM App, while the smart water delivery system provides the cat with a source of fresh water.

Each cat within a household is registered to FELAQUACONNECT via their microchip. FELAQUACONNECT integrates with the SURE PETCARE App via a Hub, which allows the App to “talk” to the device and record each registered cat’s drinking behavior such as which cat drank, what time it drank, and how much it drank. It also provides reports on the cat’s overall drinking patterns on a daily, weekly, and monthly basis. With this information, cat owners can easily detect any changes in their cat’s drinking patterns. The SURE PETCAREM App also sends reminder notifications to refill the reservoir of FELAQUA CONNECT when the water is low, and water freshness reminders to encourage cleaning of the device.

FELAQUA CONNECT has several cat-friendly features, including a wide, shallow bowl that mimics a natural puddle and presents water in a way that is more appealing and easier to drink than from a conventional bowl. The bowl is also water repellent causing the water to bead – in the same way that water stands up on a newly polished car – making it reflect and glisten and be more attractive to cats.

 The water is kept fresh in an air-tight, gravity-fed reservoir that releases water into the bowl as it is needed. Because the device is battery powered, there are no cables or need for an electrical power source, so the device can be placed in any part of the home to best suit the cat’s drinking needs.  

Dr. Jon Bowen and Dr. Jaume Fatjó, leading veterinary behaviorists, were involved in the design and development of FELAQUA CONNECT. Dr. Bowen said, “FELAQUA CONNECT provides a window into your cat’s health and highlights the importance of hydration as a health indicator. A change in water consumption is one of the most concerning health indicators in middle-aged and senior cats. Fluctuations in intake can be a sign of illnesses such as diabetes or kidney disease, and the sooner we intervene the better the outcome. Proper hydration is essential to maintain a cat’s health.”

In a recent survey conducted by Sure Petcare, over 15 hundred U.S. cat owners were surveyed. Of that number, only nine percent of respondents were able to recognize all the main signs of dehydration and over half of those pet owners were unaware that an increase in thirst was a possible sign of dehydration. 69 percent of cat owners said they couldn’t give the veterinarian an accurate answer about how much their cat drinks each day. Given that an increase in drinking is an indicator of kidney disease, and accurate information is essential for a speedy diagnosis, this lack of awareness could lead to undetected kidney disease.

“A device like FELAQUA CONNECT tells you if your cat is drinking more or less than usual,” said Dr. Bowen. “It’s this insight that is invaluable and provides peace of mind that they are drinking regularly.”

FELAQUA CONNECT is available for purchase on beginning in July. The Hub can be purchased separately from Sure Petcare’s website.

About Dr. Jon Bowen

Dr. Jon Bowen BVetMed DipAS (CABC) MRCVS is a graduate from the Royal Veterinary College in London, where he is an honorary lecturer in behaviour and head of the Behavioural Medicine Referral Service. 

About Dr. Jaume Fatjó

Dr. Jaume Fatjó DVM, Dipl.ECAWBM-BM PhD graduated in veterinary medicine and obtained his PhD from the Autonomous University of Barcelona. He is a diplomate of the European College of Animal Welfare and Behavioural Medicine.

About Merck Animal Health

For 130 years, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedIn, Facebook, and Twitter at @MerckAH.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (